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Background. Mitochondria play an important role in cellu-
lar metabolism, and their dysfunction is postulated to be
involved in metabolic disturbances. Mitochondrial DNA
is present inmultiple copies per cell. Thequantificationof
mitochondrial DNA copy number (mtDNA-CN) might be
used to assess mitochondrial dysfunction.
Objectives. We aimed to investigate the cross-sec-
tional association of mtDNA-CN with type 2 diabetes
and the potential mediating role of metabolic syn-
drome.
Methods. We examined 4812 patients from the German
Chronic Kidney Disease (GCKD) study and 9364
individuals from the Cooperative Health Research in
South Tyrol (CHRIS) study. MtDNA-CN was measured in
whole blood using a plasmid-normalized qPCR-based
assay.
Results. In both studies, mtDNA-CN showed a significant
correlation with most metabolic syndrome parameters:
mtDNA-CN decreased with increasing number of meta-
bolic syndrome components. Furthermore, individuals
with low mtDNA-CN had significantly higher odds of
metabolic syndrome (OR = 1.025; 95% CI =
1.011–1.039, P = 3.19 × 10−4, for each decrease of 10
mtDNA copies) and type 2 diabetes (OR = 1.027; 95%
CI = 1.012–1.041; P = 2.84 × 10−4) in a model adjusted
for age, sex, smoking and kidney function in the meta-
analysis of both studies.Mediation analysis revealed that
the association of mtDNA-CN with type 2 diabetes was
mainly mediated by waist circumference in the GCKD
study (66%) and by several metabolic syndrome param-
eters, especially bodymass indexand triglycerides, in the
CHRIS study (41%).
Conclusions. Our data show an inverse association of
mtDNA-CN with higher risk of metabolic syndrome and
type 2 diabetes. Amajor part of the total effect of mtDNA-
CN on type 2 diabetes ismediated by obesity parameters.
Keywords: chronic kidney disease, diabetes, meta-
bolic syndrome, mitochondrial DNA copy number.
Introduction
Mitochondria play a pivotal role in the cellular
energy metabolism. Their number varies across
tissues and cell types, depending on the energy
demand of the cell [1]. Mitochondria are dynamic
organelles that can alter their morphology in
response to changes in the cellular metabolic state.
†The GCKD Investigators listed in 1Appendix.
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They undergo continuous cycles of fission and
fusion that help to maintain a functional balance
when cells experience metabolic or environmental
stress [2].
The involvement of mitochondrial dysfunction in
metabolic syndrome and in type 2 diabetes
remains a matter of debate, as reviewed in detail
elsewhere [3–7]. Metabolic syndrome is repre-
sented by a variety of metabolic disorders including
obesity, hypertension, insulin resistance and dys-
lipidaemia, and is a precursor of type 2 diabetes,
cardiovascular disease and renal disease [8].
Especially, the kidneys have one of the highest
densities of mitochondria and a high demand on
molecular oxygen, which is mostly metabolized
within mitochondria by oxidative phosphorylation
for the production of ATP [9]. As thoroughly reviewed
recently [10], dysfunctional mitochondria are pre-
sent in kidney disease and defects include impaired
respiratory chain function, structural and network-
ing abnormalities, disrupted cellular signalling and
increased reactive oxygen species generation.
Mitochondria have their own genome, the mito-
chondrial DNA (mtDNA), which is present in mul-
tiple copies in each cell and in each mitochondrion.
The quantification of mitochondrial DNA copy
number (mtDNA-CN) could be a simple way to
assess mitochondrial function and status, and may
reflect the level of mtDNA damage [11]. Recent
epidemiological studies described an association
between mtDNA-CN and mortality, and cardiovas-
cular disease [12–17]. Furthermore, several stud-
ies have explored the relationship between mtDNA-
CN and type 2 diabetes. However, these investiga-
tions are all characterized by small sample sizes
and have led to conflicting results [18–26]. Only
few investigations have examined the role of
mtDNA-CN in metabolic syndrome. Some studies
observed that reduced mtDNA-CN correlates with
metabolic syndrome components in the general
population [27,28] and that patients with meta-
bolic syndrome have lower mtDNA-CN than con-
trols [29].
We hypothesized that increased risk of metabolic
disorders is associated with decreased mtDNA-CN.
Therefore, we quantified peripheral blood mtDNA-
CN in two large cohorts from Germany and Italy
including 4812 patients with moderate chronic
kidney disease from the GCKD (German Chronic
Kidney Disease) study and 9364 individuals from
the population-based CHRIS (Cooperative Health
Research in South Tyrol) study. We assessed the
relationship between mtDNA-CN and both meta-
bolic syndrome and type 2 diabetes in a cross-
sectional analysis. Furthermore, we investigated
the potential mediating role of metabolic syndrome
components on type 2 diabetes risk.
Materials and Methods
GCKD study
TheGCKD study is an ongoing prospective multicen-
ter observational cohort study described previously
[15]. Briefly, 5217 patients under regular care by
nephrologists were enrolled. The inclusion criteria
were moderately reduced kidney function defined as
estimated glomerular filtration rate (eGFR)
30–60 mL/min/1.73 m2 (stage G3, A1–A3) or an
eGFR >60 mL/min/1.73 m2 in the presence of overt
proteinuria (stage G1–G2, A3). The exclusion criteria
were non-Caucasian ethnicity, solid organ or bone
marrow transplantation, active malignancy within
24 months prior to screening, heart failure (NewYork
Heart Association Stage IV), legal attendance or
inability to provide consent. Information on socio-
demographic factors, medical and family history,
medications and health-related quality of life were
obtained by trained personnel through standardized
questionnaires. Data are collected and managed
using Askimed (https://www.askimed.com) as a
cloud-basedweb platform for collection andmanage-
ment of Case Report Forms and laboratory data.
CHRIS study
The CHRIS study is an ongoing longitudinal pop-
ulation-based study being carried out in South
Tyrol (Italy) that aims to investigate the molecular
and environmental determinants of common
chronic conditions associated with human ageing.
A detailed description of the study has been
published previously [30]. Blood and urine sam-
ples were collected from all participants in the early
morning following overnight fasting. Detailed infor-
mation about medical history and medication was
collected by means of interviewer and self-admin-
istered questionnaires. The current project is
based on CHRIS data release 3 (16 June 2017)
that included 10 518 individuals.
Informed consent
All participants provided written informed consent,
and both studies were carried out in accordance
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with approved guidelines and in compliance with
current national and EU regulations and the Dec-
laration of Helsinki. The GCKD study was
approved by the Ethics Committees of all partici-
pating institutions and is registered in the National
Registry for Clinical Studies (DRKS 00003971).
The CHRIS study was approved by the Ethical
Committee of the Healthcare System of the Auton-
omous Province of Bolzano (Protocol No. 21/2011).
The project ‘Variazioni del numero di copie del DNA
mitocondriale: mutazioni e suscettibilità alle
malattie’ (Principal Investigator: Andrew A. Hicks)
was approved by the same committee (Protocol No.
10/2016). Analysis of data and samples for this
project was authorized by the CHRIS Access Com-
mittee (Application No. 69).
Mitochondrial DNA copy number measurement
Biosamples of both studies were collected in a
standardized way and shipped under temperature-
controlled conditions to a central laboratory for
routine clinical chemistry and central biobank for
future analyses. DNA was extracted from frozen
ethylenediaminetetraacetic acid-treated blood
samples using the chemagic Magnetic Separation
Module I (PerkinElmer Chemagen Technologie
GmbH), an automated magnetic bead-based
method. DNA was available from 4812 and 9364
participants of the GCKD study and CHRIS study,
respectively. The quantification of mtDNA-CN per
diploid cell was performed for both studies at the
Institute of Genetic Epidemiology of the Medical
University of Innsbruck. We applied a duplex
quantitative real-time PCR assay that allows for
simultaneous targeting of a single-copy nuclear
gene (beta-2 microglobulin) and the tRNA-Leu gene
on the mtDNA as recently described [31]. A plasmid
containing both targets was included in all runs in
order to correct for interassay variability. This
method reduces the interassay variability dramat-
ically, from 21% to 7%. The mtDNA-CN was calcu-
lated using the ΔΔCq (quantification cycle) method.
Two DNA templates included in all the qPCR
plates were used to monitor the performance of
the assay over the entire study. Interassay
mtDNA-CN coefficients of variation of these two
samples analysed in 162 independent experi-
ments were 6.5% and 9.3%. All samples were
measured in triplicate. Less than 4% of the
samples were excluded from the analysis as they
had a coefficient of variation >2% within the
triplet reactions. Equal polymerase chain reaction
efficiencies for both targets were confirmed in
fivefold serial dilutions ranging from 5.0 × 106 to
320 mtDNA copies per reaction. Finally, a total of
4812 samples from the GCKD study and 9364
from the CHRIS study with mtDNA copy number
and the other clinical and outcome variables were
analysed for this study.
Outcome definitions
Metabolic syndrome was defined according to the
joint statement between several organizations [32].
The metabolic syndrome components are defined
as binary variables: (i) waist circumference
≥102 cm in men and ≥88 cm in women in GCKD
or body mass index (BMI) above the median of the
CHRIS cohort (25.1 kg/m2), (ii) fasting triglycerides
≥150 mg/dL (1.69 mmol/L) or ≥175 mg/dL
(1.98 mmol/L) for non-fasting samples and/or
drug treatment for elevated triglycerides, (iii) HDL
cholesterol <40 mg/dL (1.03 mmol/L) in males
and <50 mg/dL (1.29 mmol/L) in females and/or
drug treatment for reduced HDL cholesterol, (iv)
systolic blood pressure ≥130 mm Hg and/or dias-
tolic blood pressure ≥85 mm Hg and/or antihy-
pertensive drug treatment and (v) fasting glucose
≥100 mg/dL (5.55 mmol/L) or glycosylated hae-
moglobin HbA1c >42 mmol/mol (6%) and/or drug
treatment of elevated glucose. The presence of at
least three out of these five components constitutes
a diagnosis of metabolic syndrome.
As the GCKD study had not performedmeasurement
of triglycerides in fasting serum samples, we set the
threshold for hypertriglyceridaemia at 175 mg/dL
[33]. In the CHRIS study, waist circumference data
were not available. Therefore, BMI calculated as
(weight in kg)/(height in m2) was used as a surro-
gate. Type 2 diabetes was defined as HbA1c ≥ 48
mmol/mol (6.5%) and/or the use of an antidiabetic
medication in the GCKD study. In the CHRIS study,
type 2 diabetes was defined as self-reported doctor-
diagnosed diabetes or use of glucose-lowering drugs
or as HbA1c ≥ 48 mmol/mol (6.5%) or fasting glu-
cose ≥126 mg/dL (6.99 mmol/L).
Statistical analysis
We used pairwise Spearman’s rank-based coefficient
to assess the correlation between mtDNA-CN and all
continuous parameters involved in the metabolic
syndrome definition. The effect of mtDNA-CN on
metabolic syndrome was assessed by means of
logistic regression models adjusted for age and sex
(model 1) and additionally for baseline eGFR, urine
mtDNA copy number and metabolic syndrome / F. Fazzini et al.
ª 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine. 3
Journal of Internal Medicine
albumin-to-creatinine ratio (UACR) and smoking
status (model 2). We used the same approach to
assess the effect of mtDNA-CN on type 2 diabetes
risk by further including all metabolic syndrome
components as covariates, except for fasting glu-
cose and HbA1c, since they would be part of the
outcome definition (model 3). These analyses were
conducted for both studies separately and further
meta-analysed using a fixed-effects model (I2 for all
models = 0).
To evaluate whether the association between
mtDNA-CN and metabolic syndrome is triggered
by specific single components of metabolic syn-
drome, we also applied the same analysis using
each binary metabolic syndrome component as
outcome. In addition, we also fitted linear regres-
sion models on waist circumference and BMI, as no
specific medications are included in the compo-
nents’ definitions. Since the definition of single
components differs slightly between both studies,
no meta-analysis was conducted for the analysis of
the single components.
In the CHRIS study, models were further adjusted
to account for possible batch and protocol effects
[34], as well as for the relatedness structure of the
study sample. We fitted a generalized logistic
mixed model including the kinship matrix, utiliz-
ing the GMMAT R package [35]. The pairwise
kinship coefficients were estimated using the
‘kinship2’ R package based on genetic data. All
effect estimates refer to a decrease of 10 mtDNA
copies.
In both studies separately, we performed a formal
mediation analysis for multiple mediators apply-
ing the product method approach [36] allowing for
categorical mediators [37] to assess the propor-
tion of effect on type 2 diabetes that is mediated
by the metabolic syndrome components. Waist
circumference and BMI were included as contin-
uous variables. All other components were
included as binary variables, since their defini-
tions as metabolic syndrome components also
include medications. These models were addi-
tionally adjusted for age, sex, smoking, eGFR and
log-transformed UACR. 95% confidence intervals
were derived via bootstrap sampling using 1000
iterations.
Since peripheral blood mtDNA-CN might be influ-
enced by blood cell composition [38], we performed a
sensitivity analysis in the CHRIS study where white
blood cell and platelet count measurements were
available. For this analysis, estimated leucocytes
mtDNA-CNwascalculatedusinga formula that takes
into account the contribution of platelets:
(K is an estimated factor; we used K = 1.1 as
described by Hurtado-Roca and colleagues [38]).
All statistical analyses were performed using R
3.3.2 (https://www.r-project.org), and statistical
significance was set at alpha = 0.05.
Results
Overall, we investigated 14 176 individuals includ-
ing 4812 from the GCKD study and 9364 from the
CHRIS study. The characteristics of the study
participants can be found in Table 1. Data for the
entire group and stratified for men and women are
provided in Table S1 for the GCKD study and in
Table S2 for the CHRIS study.
Association of mtDNA-CN with single metabolic syndrome components
MtDNA-CN means and standard deviations were
107.2  36.4 in the GCKD study and 143.8  51.4
in theCHRIS study, respectively. A correlationmatrix
of mtDNA-CNwith each metabolic syndrome param-
eter ona continuous scale is provided inFigure S1 for
each study. Correlations of mtDNA-CN with meta-
bolic syndromeparametersweredirection-consistent
in both studies and were significant with obesity
parameters (waist circumference and BMI), diastolic
blood pressure, Hb1Ac and HDL cholesterol in the
GCKD study and with all parameters in the CHRIS
study. In the next step, we applied logistic regression
models between mtDNA-CN and each of the binary
metabolic syndrome component definitions, which
consider also drug use for blood pressure, HDL
cholesterol, triglycerides and glucose. In the age-
and sex-adjusted model 1, mtDNA-CN was signifi-
cantly associated with the waist circumference com-
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study and with all components in the CHRIS study
(Table 2). In model 2, additionally adjusting for
baseline eGFR, UACR and smoking status, a signif-
icant association only remained for elevated waist
circumference in GCKD, but was observed with all
components except glucose in CHRIS. Although not
significant, the ORs for the other components were
also >1 (except triglycerides in model 2), thus adding
Table 1. Characteristics of the participants and distribution of metabolic syndrome components in the GCKD study and the
CHRIS study
GCKD study (n = 4812)
Mean  SD or % (n)
[25th, 50th, 75th percentiles]
CHRIS study (n = 9364)
Mean  SD or n (%)
[25th, 50th, 75th percentiles]
mtDNA-CN 107.2  36.4 143.8  51.44
Age 60  12 [53, 63, 70] 46  16 [32, 46, 57]
Sex (female) 39.7% (1908) 55.1% (5161)
Waist circumference, cm
Women 97.4  16.5 [85.0, 96.0, 109.0] NA
Men 107.8  13.8 [98.0, 107.0, 116.1] NA
BMI, kg/m2
Women 29.6  6.8 [24.6, 28.6, 33.8] 25.3  4.9 [21.7, 24.2, 27.9]
Men 29.9  5.4 [26.2, 29.0, 32.7] 26.5  4.0 [23.7, 26.0, 28.7]
HDL cholesterol, mg/dL
Women 59.7  18.7 [46.7, 57.2, 69.8] 67.0  15.5 [56, 66, 76]
Men 46.7  15.4 [36.6, 44.0, 53.4] 54.5  13.5 [45, 53, 62]
Triglycerides, mg/dL 198  125 [117, 168, 240] 104  66 [65, 87, 123]
Total cholesterol, mg/dL 211  53 [176, 207, 239] 211  41 [182, 209, 237]
LDL cholesterol, mg/dL 118  44 [89, 114, 143] 131.45  37.26 [105, 129, 155]
Non-HLD cholesterol, mg/dL 159  50 [125, 153, 186] 150  41 [120, 146, 176]
Uric acid, mg/dL 7.2  1.9 [5.9, 7.1, 8.3] 5.2  1.4 [4.2, 5.1, 6.1]
Systolic blood pressure, mm Hg 139.5  20.2 [126, 138, 152] 122.2  16.4 [111, 120, 131]
Diastolic blood pressure, mm Hg 79.1  11.7 [71, 79, 87] 78.3  9.4 [72, 77, 84]
Fasting glucose, mg/dL NA 92.2  13.3 [85, 90, 97]
Glycosylated haemoglobin (HbA1c) 6.3  1.0 [5.7, 6.0, 6.6] 5.56  0.47 [5.3, 5.5, 5.8]
eGFR, mL/min per 1.73 m2 49.4  18.2 [37, 46, 58] 91.8  16.3 [81.1, 92.0, 103.1]
UACR, mg/g 432.0  969.6 [9.7, 50.7, 391.0] 15.7  80.0 [4.0, 6.0, 10.6]
Current smokers 15.9% (767) 18% (1687)
Elevated waist circumference or BMI 67.3% (3149) 50.3% (4708)
Elevated blood pressure and/or
antihypertensive drug treatment
97.8% (4702) 37.3% (3495)
Reduced HDL cholesterol and/or
drug treatment for reduced HDL-C
36.2% (1730) 11.5% (1077)
Elevated triglycerides and/or
drug treatment for elevated triglycerides
49.1% (2352) 14.6% (1367)
Elevated glucose and/or
drug treatment of elevated glucose
51% (2437) 17.8% (1666)
Metabolic syndrome 64% (3039) 18.7% (1754)
Type 2 diabetes 35.9% (1726) 4.41% (413)
NA, not available.
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to the association with metabolic syndrome. The
linear regression model on waist circumference as a
continuous variable using the extended adjustment
model (model 2) was also significant in the GCKD
study (β = 0.3640 for each decrease of 10 mtDNA
copies, P = 6.86 × 10−10).
Association of mtDNA-CN with metabolic syndrome
Mean values of mtDNA-CN are displayed in Fig. 1,
revealing that with decreasing mtDNA-CN the num-
ber of metabolic syndrome components increased in
both studies (Fig. 1). Logistic regression models
Table 2. Results of logistic regression between mitochondrial DNA copy number and metabolic syndrome components
Metabolic syndrome components
GCKD CHRISa
OR 95% CI P-value OR 95% CI P-value
Model 1: adjusting for age and sex
Elevated WC (GCKD)/BMI (CHRIS) 1.045 1.027–1.064 4.81 × 10−07 1.019 1.010–1.028 3.84 × 10−05
Elevated triglycerides 1.004 0.998–1.020 0.61 1.025 1.012–1.038 1.29 × 10−04
Reduced HDL cholesterol 1.006 0.990–1.023 0.46 1.028 1.013–1.043 2.77 × 10−04
Elevated blood pressure 1.054 1.005–1.102 0.0248 1.012 1.003–1.022 0.0139
Elevated Hb1Ac (GCKD)/
fasting glucose (CHRIS)
1.012 0.995–1.029 0.16 1.013 1.001–1.025 0.0385
Model 2: adjusting for age, sex, smoking, eGFR and UACR
Elevated WC (GCKD)/BMI (CHRIS) 1.045 1.027–1.064 6.69 × 10−07 1.017 1.008–1.026 1.58 × 10−04
Elevated triglycerides 0.999 0.983–1.015 0.89 1.020 1.007–1.034 0.0023
Reduced HDL cholesterol 1.001 0.984–1.018 0.92 1.024 1.009–1.040 0.0016
Elevated blood pressure 1.044 0.995–1.093 0.07 1.012 1.002–1.022 0.0239
Elevated Hb1Ac (GCKD)/
fasting glucose (CHRIS)
1.010 0.992–1.027 0.28 1.010 0.998–1.023 0.09
Odds ratios (OR) are given for decrease of 10 mtDNA copies. The bold values should point out which findings are
statistically significant.
eGFR, estimated glomerular filtration rate; Hb1Ac, glycated haemoglobin; UACR, urine albumin-to-creatinine ratio; WC,
waist circumference.
aCHRIS study additionally adjusted for protocol, batch and kinship matrix (see Supplementary Material).
Fig. 1 Mean values and corresponding 95% confidence intervals of mtDNA copy numbers for each stratum of numbers of
metabolic syndrome components, prevalence of metabolic syndrome and prevalence of type 2 diabetes at baseline in two
independent cohorts: GCKD (n = 4812) study and CHRIS study (n = 9364).
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adjusting for different sets of variables showed a
significant association between a low mtDNA copy
number and the odds of metabolic syndrome, with
similar results for both studies (Table 3). In themeta-
analysis of both studies, the OR was 1.025
(P = 3.19 × 10−4) for each 10 mtDNA-CN decrease
in model 2. There was a significant interaction with
sex (P = 0.0382 in GCKD and P < 2 × 10−16, in
CHRIS), with higher OR in men (OR = 1.046; 95%
CI = 1.023–1.070, P = 7.67 × 10−5, in GCKD and
OR = 1.030, 95% CI = 1.013–1.046, P = 3.2 × 10−4,
in CHRIS) than in women (OR = 1.000, 95% CI =
0.976–1.030, P = 0.83, in GCKD; and OR = 1.017,
95% CI = 0.998–1.036, P = 0.07, in CHRIS). Fur-
thermore, we performed a sensitivity analysis using a
formula to calculate mtDNA-CN taking into account
both leucocyte count and platelet count [38]. This
additional analysis resulted in onlymarginal changes
in the ORs for metabolic syndrome in CHRIS (model
2, OR = 1.016; 95% CI = 1.003–1.029, P = 0.0131).
Association of mtDNA-CN with type 2 diabetes
Low mtDNA-CN was also significantly associated
with higher odds of type 2 diabetes. In model 1, we
detected a 2.8% higher odds for diabetes per decrease
of 10 mtDNA-CN (OR = 1.028; P = 4.56 × 10−5),
which remained significant with similar odds in
model 2 (OR = 1.027; P = 2.84 × 10−4). There was
no significant interaction with sex (P = 0.27 for
GCKD and P = 0.75 for CHRIS).
Mediation analysis
When we adjusted in a third model for the
variables contributing to the metabolic syndrome
components, the association between mtDNA-CN
and type 2 diabetes was no longer significant
(model 3 in Table 3, P = 0.15). This indicates that
the effect of mtDNA-CN on type 2 diabetes risk
might be mediated by metabolic syndrome
parameters. Providing there is a causal increasing
effect of lower mtDNA-CN on some of the param-
eters, it might be a reasonable assumption that it
is the increase in, for example, obesity or other
parameters that increase type 2 diabetes risk,
implying that the effect of mtDNA on type 2
diabetes risk is indirect. We therefore performed
a formal mediation analysis to evaluate this
hypothesis, starting by verifying the requirements
for mediation. The first requirement is that
mtDNA-CN is associated with the outcome vari-
able (metabolic syndrome/type 2 diabetes), which
was fulfilled (models 1 and 2, Table 3). The
second assumption is that mtDNA-CN is associ-
ated with its potential mediators. In model 2, this
was only true for waist circumference in GCKD,
but was true for all single components in the
CHRIS study. Furthermore, mediators have to be
associated with type 2 diabetes when adjusted for
mtDNA-CN. This was also fulfilled for waist
circumference in GCKD and for four components
in CHRIS (Table 2). Therefore, only waist circum-
ference fulfilled the criterion of a potential medi-
ating variable in GCKD, but all four components
qualified in the CHRIS study. For comparability,
all four components were included in the media-
tion model also in the GCKD study. 66% of the
total effect of mtDNA-CN on type 2 diabetes was
mediated by waist circumference in the GCKD
study (Fig. 2 and Table S3). The other metabolic
syndrome components did not contribute. In the
Table 3. Results of logistic regression analysis of mitochondrial DNA copy numbers on metabolic syndrome and type 2
diabetes risk in GCKD and CHRIS study
Adjustment modelb
GCKD CHRISa Meta-analysis
OR [95% CI] P-value OR [95% CI] P-value OR [95% CI] P-value
Metabolic syndrome
Model 1 1.032 [1.014–1.049] 2.9 × 10−04 1.029 [1.017–1.042] 0.0015 1.030 [1.020–1.040] 1.53 × 10−09
Model 2 1.027 [1.009–1.040] 0.0025 1.023 [1.001–1.046] 0.0070 1.025 [1.011–1.039] 3.19 × 10−04
Type 2 diabetes
Model 1 1.030 [1.012–1.049] 8.6 × 10−04 1.026 [1.004–1.049] 0.0206 1.028 [1.015–1.043] 4.56 × 10−05
Model 2 1.029 [1.011–1.048] 0.0016 1.022 [0.999–1.047] 0.06 1.027 [1.012–1.041] 2.84 × 10−04
Model 3 1.010 [0.990–1.030] 0.33 1.013 [0.990–1.037] 0.27 1.011 [0.996–1.026] 0.15
Odds ratios (OR) are given for decrease of 10 mtDNA copies. The bold values should point out which findings are
statistically significant.
Model 2: as model 1 further adjusted for smoking status, eGFR and UACR
Model 3: as model 2 further adjusted for waist circumference, triglycerides, blood pressure (systolic and diastolic) and
HDL cholesterol.
aCHRIS study additionally adjusted for protocol, batch and kinship matrix (see Supplementary Material).
bModel 1: adjusted for age and sex.
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CHRIS study, 41% of the effect of mtDNA-CN on
type 2 diabetes risk was mediated by the four
components in total, with about 23% mediated by
BMI, 4.6% by the HDL component and 6.6% by
each triglyceride and blood pressure component.
The mediating effects of HDL cholesterol and
blood pressure did not contribute significantly,
though.
Discussion
The current study including 4812 patients with
moderately severe chronic kidney disease and
9364 individuals from a general population sample
found mtDNA-CN to be significantly associated
with the prevalence of metabolic syndrome and
type 2 diabetes. Furthermore, mediation analysis
revealed that a major part of the total effect of
mtDNA-CN on type 2 diabetes was mediated by
waist circumference and BMI, respectively.
Association with metabolic syndrome
To our knowledge, only two small observational
studies have previously investigated the associa-
tion between mtDNA-CN and metabolic syndrome
[28,29]. The case–control study by Huang et al.
including 80 patients with metabolic syndrome
and 50 controls revealed that metabolic syndrome
patients had lower mtDNA-CN than control sub-
jects (358  325 vs. 233  112 mtDNA-CN per cell)
[29]. This difference might be a marked overesti-
mation compared with our two cohorts, where we
found roughly 5% and 7% difference between
subjects with and without metabolic syndrome in
GCKD and CHRIS, respectively. Kim et al. in a
study with 144 women reported similar findings as
in our study [28].
In a longitudinal study with 989 participants,
Révész and colleagues showed that mtDNA-CN at
baseline did not predict individual metabolic syn-
drome component changes during a 10-year per-
iod. Nevertheless, metabolic syndrome diagnosis,
waist circumference and fasting glucose levels
predicted a 10-year decrease in mtDNA-CN [27].
Additional studies explored the association
between mtDNA-CN and various single metabolic
parameters, with contradictory results. The major-
ity of these studies [16,39–41] with two exceptions
[42,43] reported an inverse association between
mtDNA-CN and metabolic syndrome components.
In one of the largest studies performed so far that
included only women, the authors demonstrated
that mtDNA-CN had little or no association with 12
cardiometabolic risk factors in 5150 women [42].
This is in line with our sex-specific analysis, in
which we also failed to find an association between
mtDNA-CN and metabolic syndrome in women.
In our study, waist circumference (respectively,
BMI) had the strongest association with mtDNA-CN
amongst the metabolic syndrome components.
This association is in line with some previous
smaller studies [18,39,41,43,44].
Association with type 2 diabetes
The relation between mtDNA-CN with type 2 dia-
betes and insulin resistance has been explored in
several prior studies. These investigations, carried
out in a variety of tissues and cell types, are mostly
characterized by small sample sizes and inconsis-
tent results: type 2 diabetes was reported to be
associated with either an increase [20,23,24] or a
decrease in mtDNA-CN [18,19,21,22,26].
Fig. 2 Results of the mediation analysis, depicting the proportion of the total effect of mtDNA copy number on type 2
diabetes mediated by metabolic syndrome components (i.e. indirect effects) and the direct effect in the GCKD study (left
panel) and CHRIS study (right panel). The thickness of the lines is proportional to the proportion mediated (n.s.: proportion
mediated does not significantly differ from 0).
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We observed a strong association between mtDNA-
CN and type 2 diabetes in both the GCKD and
CHRIS studies, independent of age, sex and kid-
ney function. After adjustment for all components
of the metabolic syndrome, the association was no
longer significant. We therefore performed a medi-
ation analysis, which revealed that the association
of mtDNA-CN with type 2 diabetes is to a major
part mediated by waist circumference in GCKD
and by BMI in CHRIS, and to a lesser extent by
triglycerides, HDL cholesterol and blood pressure.
Despite all similarities in association between
mtDNA-CN and metabolic syndrome and type 2
diabetes between the two studies, results of medi-
ation analysis differed in extent and proportion of
mediation. Notably, when taking BMI instead of
waist circumference in the GCKD study, percent-
age mediated was 52%. Therefore, only a small
part of the difference can be explained by using
different obesity parameters. Since CHRIS is pop-
ulation-based, but GCKD includes chronic kidney
disease patients, prevalences of metabolic syn-
drome components differ quite substantially, espe-
cially for hypertension, HDL cholesterol and
triglycerides. It is also a known phenomenon that
risk factors differ between chronic kidney disease
patients and population-based cohorts. Therefore,
differences have to be expected. However, the
overall conclusions of both mediation analyses
are quite similar, since in both studies, obesity
parameters contribute by far the most. Why waist
circumference in the GCKD cohort prominently
mediated two third of the association between
mtDNA-CN and diabetes might be explained by the
idea that waist circumference is the common
pathway of several quite frequent risk factors
including other unmeasured metabolic disar-
rangements in the CKD population, which end
finally in diabetes mellitus. Therefore, CKD
patients and especially those with a high waist
circumference might be closer to a tipping point
towards diabetes than the general population
sample from the CHRIS study.
It should be noted that it is a prerequisite of a
mediation analysis that one assumes a causal
relationship. In our study, one would assume that
mitochondrial function with mtDNA-CN as a sur-
rogate marker causally affects both obesity and
type 2 diabetes. However, whether the relationship
is indeed causal and in which direction cannot be
shown in observational epidemiological studies
such as ours. Based on the assumption of a causal
effect of mtDNA-CN on metabolic syndrome
components, we could then show that mitochon-
drial dysfunction increases diabetes risk mainly by
increasing central obesity.
Potential mechanism
Although we cannot infer any causal direction of the
relationship between mtDNA-CN and metabolic syn-
drome from our data, additional evidence supports
this assumption. For example, studies in both
humans and animals have shown a loss of mtDNA
content in metabolic diseases [45]. The pathophysi-
ological mechanism underlying this association has
not yet been fully elucidated. However, a ‘metabolic
oversupply’ characterized by an excess of energy
substrates (e.g. lipids, glucose) not only endorses
deterioration of other metabolic syndrome compo-
nents (e.g. insulin resistance) but also increases
cytokine-mediated inflammation, and induces mito-
chondrial fragmentation and oxidative stress [27].
This latter is a state that occurs with elevated
intracellular levels of reactive oxygen species due to
an imbalance between the production of these sub-
stances and antioxidant defences. Mitochondrial
DNA, owing to its proximity to the electron transport
chain, is the prime target of reactive oxygen species
[46]. Increased mtDNA damage leads to impaired
enzymatic activity and mitochondrial dysfunction,
which promotes the development of pathological
conditions such as metabolic disorders, ageing and
cancer. In contrast, metabolic ‘undersupply’, result-
ing from caloric restriction and moderate physical
activity, increases energy substrate utilization, pro-
motes mitochondrial fusion and limits mtDNA dam-
age [27,47]. Similarly, it has been shown that
hyperglycaemia increases the expression of fission
proteins [48] (e.g. dynamin-related protein 1) and
reduces the expression of fusion proteins [47,49] (e.g.
mitofusin 2 and Opa1).
Strengths and limitations of the study
There are several strengths of our study. We
analysed data from 14 176 study participants that
include both chronic kidney disease patients and
general population individuals. To our knowledge,
this is one of the largest investigations of mtDNA-
CN and metabolic disorders. We used the same
DNA extraction method for both studies, and the
mtDNA-CN quantification of all samples was per-
formed in a single laboratory using a plasmid
normalization approach for correction for interas-
say variability. This is a significant advantage,
since the DNA extraction method can affect
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tremendously the mtDNA-CN quantification
results [31]. This study has also some limitations:
mtDNA-CN was measured in DNA extracted from
total peripheral blood cells. It was not possible to
provide data for individual blood cells populations.
We acknowledge that other methods could be more
appropriate to assess mitochondrial biogenesis
and activity, such as the measurement of citrate
synthase, oxygen consumption rate or quantifica-
tion of the mRNA. However, the majority of these
methods are performed using tissues, cultured cell
or blood that should be drawn and stored following
specific conditions. Therefore, all these approaches
are not feasible in large epidemiological studies
with thousands of participants. Peripheral blood
has the advantage that is easily accessible, on the
contrary may not reflect mitochondrial function in
tissues that contributes to insulin resistance (e.g.
skeletal muscle and adipose tissue). However,
tissue biopsies are invasive and their use in
epidemiological studies is hardly feasible. A further
limitation is that waist circumference as a classical
component of metabolic syndrome was not mea-
sured in the CHRIS study; therefore, BMI was used
as a surrogate of waist, which is also used in the
American Association of Clinical Endocrinologists
(AACE) metabolic syndrome definition [50]. Finally,
we consider the use of HbA1c instead of fasting
blood glucose as an advantage since HbA1c might
be a more stable metabolic index with less prean-
alytical instability and less biologic variability [51].
The disparity in mtDNA-CN values between our two
studies can be partially explained by the differ-
ences in the enrolled populations: chronic kidney
disease patients in GCKD and a general population
in CHRIS. In the last decade, many studies
reported that lower mtDNA-CN was associated
with ageing and various human diseases, including
chronic kidney disease [52]. The huge differences
in kidney parameters (eGFR and UACR) and age
between the CHRIS and GCKD might explain
roughly 30% of the difference in mtDNA-CN values.
As discussed previously [31], the measured
mtDNA-CN might be influenced by various factors
such as preanalytical conditions including DNA
preparation and storage, and standardization of
measurement. Therefore, the absolute numbers
should not be taken into consideration, and com-
parisons between studies not measured within the
same assay batches should be avoided. We there-
fore analysed each study separately and then
meta-analysed the results. Despite these differ-
ences between the two study populations, it is
quite impressive that the main conclusions are
valid for both studies.
A further limitation is that chronic kidney disease
in the GCKD study could have added complexities
that might not simply be reflected or adjusted for
by eGFR and albuminuria. We cannot exclude
that any potential confounders not reflected in the
classical kidney function measures have an
impact on bone marrow function and thereby
potentially affecting leucocytes and mitochondrial
properties.
Conclusions
In summary, we found lower mtDNA-CN to be
strongly associated with metabolic syndrome and
type 2 diabetes both in chronic kidney disease
patients and in the general population. The medi-
ation analysis suggested that a major part of the
total effect of mtDNA-CN on type 2 diabetes was
mediated by obesity parameters.
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